Elevance Health Q1 Revenue Exceeds Expectations at $49.5B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ELV?
Reports Q1 revenue $49.5B, consensus $47.98B. "Our first quarter results exceeded expectations, reflecting underlying business strength and improving claims experience. We are raising our full-year adjusted EPS guidance, supported by greater visibility into the balance of the year. Our actions are driving more consistent performance and position Elevance Health for continued improvement over time," said Gail Boudreaux, President and Chief Executive Officer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to rise
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 346.290
Low
332.00
Averages
389.07
High
425.00
Current: 346.290
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elevance Health Exceeds Q1 2026 Earnings Expectations
- Earnings Beat: Elevance Health reported an adjusted diluted EPS of $12.58 for Q1 2026, exceeding expectations by $1.77, driven by strong underlying business performance, ACA seasonality, and nonrecurring investment income, prompting a full-year EPS guidance increase to at least $26.75.
- Revenue Growth: Operating revenue reached $49.5 billion in the first quarter, reflecting a 1.5% year-over-year increase, while membership grew to 45.4 million, an increase of nearly 200,000 from year-end, indicating sustained competitiveness and customer attraction in the market.
- Cost Control and Investment: The company anticipates achieving an operating margin of at least 2% in 2026 and plans to repurchase at least $2.3 billion in shares, demonstrating a commitment to optimizing capital structure and enhancing shareholder returns.
- Strategic Realignment and AI Investment: Elevance has realigned its leadership structure to strengthen coordination between health benefits and Carelon, while embedding and scaling AI across clinical, operational, and administrative workflows to drive higher engagement and improved clinical outcomes, positioning for long-term growth.
See More
ELEVANCE HEALTH: LEERINK PARTNERS INCREASES TARGET PRICE TO $364, UP FROM $357
Price Increase Announcement: Lee Rink Partners has raised the target price for a specific stock to $364 from a previous price of $357.
Market Implications: This adjustment in target price may reflect positive expectations for the company's performance or market conditions.
See More
Elevance Health Faces Investigation Over CMS Sanctions
- CMS Sanction Notification: On March 2, 2026, Elevance Health disclosed that the Centers for Medicare & Medicaid Services (CMS) intends to impose intermediate sanctions due to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements, which could significantly disrupt its business operations.
- Stock Price Decline: Following the announcement of the sanctions, Elevance's stock price plummeted from $320.00 on February 27, 2026, to $294.07, marking an 8.1% decline, indicating market concerns regarding the company's compliance issues.
- Ongoing Legal Investigation: Kirby McInerney LLP is conducting an investigation on behalf of Elevance investors to determine potential violations of federal securities laws, although no lawsuits have been filed yet, the investigation may lead to future legal actions.
- Investor Rights Protection: Investors who purchased Elevance shares during this period are encouraged to contact Kirby McInerney LLP to discuss their rights, highlighting the firm's commitment to protecting investor interests amidst these developments.
See More
Elevance Health (ELV) Q1 2025 Earnings Transcript
See More
Analysis of Significant Stock Movements Among Companies
- Calix Stock Decline: Calix's shares fell 16% after the company warned of margin pressures for the year, overshadowing better-than-expected first-quarter results, indicating investor concerns about future profitability.
- TE Connectivity Guidance Miss: TE Connectivity's stock dropped 12% as the company's second-quarter guidance of $2.65 EPS and $4.7 billion revenue aligned with FactSet consensus but failed to inspire investor confidence, leading to downward pressure on the stock.
- Healthcare Services Group Strong Performance: Healthcare Services Group's shares surged 18% after reporting a first-quarter profit of $0.37 per share and revenue of $462.8 million, both exceeding analyst expectations, showcasing the company's competitive edge and growth potential in the market.
- United Airlines Guidance Cut: United Airlines shares fell 6% after the company provided disappointing guidance for the current quarter and full year, expecting adjusted earnings of $7 to $11 per share for 2026, down from prior estimates of $12 to $14, reflecting rising fuel price pressures.
See More
Elevance Health Declares Quarterly Dividend of $1.72
- Quarterly Dividend Announcement: Elevance Health declares a quarterly dividend of $1.72 per share, consistent with previous distributions, indicating the company's stable cash flow and profitability, which is likely to attract more investor interest.
- Dividend Yield: The forward yield of 2.04% reflects the company's competitiveness in the current market environment, potentially boosting shareholder confidence and enhancing stock performance.
- Shareholder Record Dates: The dividend is payable on June 25, with a record date of June 10 and an ex-dividend date also on June 10, providing investors with a clear timeline to participate in the dividend distribution.
- Earnings Beat: Elevance Health reported a non-GAAP EPS of $12.58, beating expectations by $1.77, with revenue of $49.5 billion exceeding forecasts by $1.52 billion, showcasing the company's success in cost control and further enhancing market confidence in its future growth.
See More
Elevance Health Exceeds Q1 2026 Earnings Expectations
- Earnings Beat: Elevance Health reported an adjusted diluted EPS of $12.58 for Q1 2026, exceeding expectations by $1.77, driven by strong underlying business performance, ACA seasonality, and nonrecurring investment income, prompting a full-year EPS guidance increase to at least $26.75.
- Revenue Growth: Operating revenue reached $49.5 billion in the first quarter, reflecting a 1.5% year-over-year increase, while membership grew to 45.4 million, an increase of nearly 200,000 from year-end, indicating sustained competitiveness and customer attraction in the market.
- Cost Control and Investment: The company anticipates achieving an operating margin of at least 2% in 2026 and plans to repurchase at least $2.3 billion in shares, demonstrating a commitment to optimizing capital structure and enhancing shareholder returns.
- Strategic Realignment and AI Investment: Elevance has realigned its leadership structure to strengthen coordination between health benefits and Carelon, while embedding and scaling AI across clinical, operational, and administrative workflows to drive higher engagement and improved clinical outcomes, positioning for long-term growth.
See More
ELEVANCE HEALTH: LEERINK PARTNERS INCREASES TARGET PRICE TO $364, UP FROM $357
Price Increase Announcement: Lee Rink Partners has raised the target price for a specific stock to $364 from a previous price of $357.
Market Implications: This adjustment in target price may reflect positive expectations for the company's performance or market conditions.
See More
Elevance Health Faces Investigation Over CMS Sanctions
- CMS Sanction Notification: On March 2, 2026, Elevance Health disclosed that the Centers for Medicare & Medicaid Services (CMS) intends to impose intermediate sanctions due to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements, which could significantly disrupt its business operations.
- Stock Price Decline: Following the announcement of the sanctions, Elevance's stock price plummeted from $320.00 on February 27, 2026, to $294.07, marking an 8.1% decline, indicating market concerns regarding the company's compliance issues.
- Ongoing Legal Investigation: Kirby McInerney LLP is conducting an investigation on behalf of Elevance investors to determine potential violations of federal securities laws, although no lawsuits have been filed yet, the investigation may lead to future legal actions.
- Investor Rights Protection: Investors who purchased Elevance shares during this period are encouraged to contact Kirby McInerney LLP to discuss their rights, highlighting the firm's commitment to protecting investor interests amidst these developments.
See More
Elevance Health (ELV) Q1 2025 Earnings Transcript
See More
Analysis of Significant Stock Movements Among Companies
- Calix Stock Decline: Calix's shares fell 16% after the company warned of margin pressures for the year, overshadowing better-than-expected first-quarter results, indicating investor concerns about future profitability.
- TE Connectivity Guidance Miss: TE Connectivity's stock dropped 12% as the company's second-quarter guidance of $2.65 EPS and $4.7 billion revenue aligned with FactSet consensus but failed to inspire investor confidence, leading to downward pressure on the stock.
- Healthcare Services Group Strong Performance: Healthcare Services Group's shares surged 18% after reporting a first-quarter profit of $0.37 per share and revenue of $462.8 million, both exceeding analyst expectations, showcasing the company's competitive edge and growth potential in the market.
- United Airlines Guidance Cut: United Airlines shares fell 6% after the company provided disappointing guidance for the current quarter and full year, expecting adjusted earnings of $7 to $11 per share for 2026, down from prior estimates of $12 to $14, reflecting rising fuel price pressures.
See More
Elevance Health Declares Quarterly Dividend of $1.72
- Quarterly Dividend Announcement: Elevance Health declares a quarterly dividend of $1.72 per share, consistent with previous distributions, indicating the company's stable cash flow and profitability, which is likely to attract more investor interest.
- Dividend Yield: The forward yield of 2.04% reflects the company's competitiveness in the current market environment, potentially boosting shareholder confidence and enhancing stock performance.
- Shareholder Record Dates: The dividend is payable on June 25, with a record date of June 10 and an ex-dividend date also on June 10, providing investors with a clear timeline to participate in the dividend distribution.
- Earnings Beat: Elevance Health reported a non-GAAP EPS of $12.58, beating expectations by $1.77, with revenue of $49.5 billion exceeding forecasts by $1.52 billion, showcasing the company's success in cost control and further enhancing market confidence in its future growth.
See More
